Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.

Abstract

Brivaracetam is the latest approved antiepileptic drug in focal epilepsy and exhibits high affinity as SV2A-ligand. More than two thousand patients have received brivaracetam within randomized placebo-controlled trials. Significant median seizure reduction rates of 30.5% to 53.1% for 50 mg/d, 32.5% to 37.2% for 100 mg/d and 35.6% for 200 mg/d were reported. Likewise, 50% responder rates were 32.7% to 55.8% for 50 mg/d, 36% to 38.9% for 100 mg/d and 37.8% for 200 mg/d. Overall, brivaracetam is well tolerated. The main adverse events are fatigue, dizziness, and somnolence. Immediate switch from levetiracetam to brivaracetam at a conversion ratio between 10:1 to 15:1 is feasible, and might alleviate the behavioral side effects associated with levetiracetam. Brivaracetam has the potential to perform as an important, possibly broad-spectrum AED, initially in patients with drug-refractory epilepsies. Its intravenous formulation may be a new and desirable alternative for status epilepticus, but there is so far no experience in these patients.

• Authors: Adam Strzelczyk, Karl Martin Klein, Laurent M Willems, Felix Rosenow, Sebastian Bauer
• Journal: Expert review of clinical pharmacology (Expert Rev Clin Pharmacol) Vol. 9 Issue 5 Pg. 637-45 ( 2016) ISSN: 1751-2441 [Electronic] England
• PMID: 26891946 (Publication Type: Journal Article, Review)

Chemical References

• Anticonvulsants
• Pyrrolidinones
• brivaracetam

Topics

• Anticonvulsants (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
• Epilepsy (drug therapy)
• Humans
• Pyrrolidinones (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)